SG10202007643SA - Stable crystal form of tipiracil hydrochloride and crystallization method for the same - Google Patents

Stable crystal form of tipiracil hydrochloride and crystallization method for the same

Info

Publication number: SG10202007643SA
Authority: SG; Singapore
Prior art keywords: same; crystal form; crystallization method; stable crystal; tipiracil hydrochloride
Prior art date: 2013-06-17

Application number

SG10202007643SA

Other languages

English (en)

Inventor

Hideki Kazuno

Tomonobu Mutsumi

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-06-17

Filing date

2014-06-17

Publication date

2020-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52104609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202007643S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-06-17 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2020-09-29 Publication of SG10202007643SA publication Critical patent/SG10202007643SA/en

Links

239000013078 crystal Substances 0.000 title 1
238000002425 crystallisation Methods 0.000 title 1
229960001740 tipiracil hydrochloride Drugs 0.000 title 1
KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)

SG10202007643SA 2013-06-17 2014-06-17 Stable crystal form of tipiracil hydrochloride and crystallization method for the same SG10202007643SA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2013126567		2013-06-17

Publications (1)

Publication Number	Publication Date
SG10202007643SA true SG10202007643SA (en)	2020-09-29

Family

ID=52104609

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SG10202007643SA SG10202007643SA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
SG10201710916YA SG10201710916YA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
SG10201912293UA SG10201912293UA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
SG11201509189SA SG11201509189SA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
SG10201710916YA SG10201710916YA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
SG10201912293UA SG10201912293UA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
SG11201509189SA SG11201509189SA (en)	2013-06-17	2014-06-17	Stable crystal form of tipiracil hydrochloride and crystallization method for the same

Country Status (31)

Country	Link
US (3)	US9527833B2 (pl)
EP (2)	EP3012255B1 (pl)
JP (2)	JP6364409B2 (pl)
KR (1)	KR101806346B1 (pl)
CN (4)	CN106967051A (pl)
AU (3)	AU2014282281C1 (pl)
BR (1)	BR112015031619B1 (pl)
CA (2)	CA2985006C (pl)
CY (1)	CY1124868T1 (pl)
DK (1)	DK3012255T3 (pl)
ES (1)	ES2898408T3 (pl)
GE (3)	GEAP201814034A (pl)
HK (1)	HK1203071A1 (pl)
HR (1)	HRP20211903T1 (pl)
HU (1)	HUE057352T2 (pl)
LT (1)	LT3012255T (pl)
MA (1)	MA38668B2 (pl)
MX (2)	MX2015016986A (pl)
MY (2)	MY205261A (pl)
NZ (1)	NZ714090A (pl)
PH (1)	PH12015502809B1 (pl)
PL (1)	PL3012255T3 (pl)
PT (1)	PT3012255T (pl)
RS (1)	RS62691B1 (pl)
RU (2)	RU2674441C1 (pl)
SG (4)	SG10202007643SA (pl)
SI (1)	SI3012255T1 (pl)
SM (1)	SMT202100689T1 (pl)
TW (1)	TWI639592B (pl)
UA (1)	UA112626C2 (pl)
WO (1)	WO2014203877A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3012255T3 (da)	2013-06-17	2021-12-06	Taiho Pharmaceutical Co Ltd	Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil
CN104744443A (zh) *	2013-12-26	2015-07-01	江苏豪森药业股份有限公司	嘧啶二酮类化合物盐酸盐新晶型及其制备方法
CN103788075B (zh) *	2014-02-19	2018-03-27	齐鲁制药有限公司	一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法
CN104945385A (zh) *	2014-03-31	2015-09-30	江苏豪森药业股份有限公司	Tipracil盐酸盐的新晶型及其制备方法
CN106018573B (zh) *	2016-03-16	2018-09-18	江苏悦兴药业有限公司	一种tas-102中盐酸替比拉西的纯度检测方法
CN105859691A (zh) *	2016-04-07	2016-08-17	扬子江药业集团南京海陵药业有限公司	一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法
WO2018039359A1 (en) *	2016-08-23	2018-03-01	Board Of Regents, The University Of Texas System	Methods for the treatment of cancer-associated bone disease
WO2019002407A1 (en) *	2017-06-28	2019-01-03	Amneal Pharmaceuticals Company Gmbh	PROCESS FOR THE PREPARATION OF TIPIRACIL CHLORHYDRATE
CN107216314A (zh) *	2017-08-02	2017-09-29	国药心制药有限公司	一种盐酸替匹嘧啶的晶型及其制备方法
WO2019049174A1 (en) *	2017-09-07	2019-03-14	Msn Laboratories Private Limited, R&D Center	SOLID STATE FORMS OF 5-CHLORO-6 - [(2-IMINOPYRROLIDIN-1-YL) METHYL] PYRIMIDINE-2,4- (1H, 3H) -DIONE HYDROCHLORIDE AND METHODS OF PREPARATION THEREOF
EP3681880A4 (en) *	2017-09-14	2021-06-23	Aurobindo Pharma Limited	PROCESS FOR THE PREPARATION OF CRYSTALLINE TIPIRACIL HYDROCHLORIDE
ES2987509T3 (es) *	2017-11-02	2024-11-15	Procos Spa	Proceso para la preparación de la forma cristalina III de clorhidrato de tipiracilo
WO2019171394A1 (en)	2018-03-03	2019-09-12	Natco Pharma Limited	Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69629156T2 (de)	1995-03-29	2004-05-06	Taiho Pharmaceutical Co. Ltd.	Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
US6255314B1 (en)	1996-09-24	2001-07-03	Taiho Charmaceutical Co., Ltd.	Cancerous metastasis inhibitors containing uracil derivatives
JP4049477B2 (ja)	1999-03-23	2008-02-20	大鵬薬品工業株式会社	副作用軽減剤
JP4110347B2 (ja)	1999-11-05	2008-07-02	大鵬薬品工業株式会社	抗ｈｉｖ剤
US7799783B2 (en) *	2005-01-26	2010-09-21	Taiho Pharmaceutical Co., Ltd.	Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
CA2649256C (en)	2006-04-13	2013-09-10	Taiho Pharmaceutical Co., Ltd.	Therapeutic agent for inflammatory bowel disease
US8148381B2 (en) *	2006-06-30	2012-04-03	Taiho Pharmaceutical Co., Ltd.	Potentiator of radiation therapy
DK3012255T3 (da)	2013-06-17	2021-12-06	Taiho Pharmaceutical Co Ltd	Stabil krystalform af tipiracilhydrochlorid og krystalliseringsfremgangsmåde dertil
CN103613877B (zh) *	2013-11-20	2017-09-19	上海锦湖日丽塑料有限公司	适于吹塑成型的高耐热abs树脂组合物及其制备方法
CN104744443A (zh)	2013-12-26	2015-07-01	江苏豪森药业股份有限公司	嘧啶二酮类化合物盐酸盐新晶型及其制备方法
CN103788075B (zh) *	2014-02-19	2018-03-27	齐鲁制药有限公司	一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法
CN104945384B (zh)	2014-03-25	2018-10-16	江苏豪森药业集团有限公司	5-氯-6-[(2-亚氨基-1-吡咯烷)甲基]-2,4(1h,3h)-嘧啶二酮或其盐的制备方法
CN104945385A (zh)	2014-03-31	2015-09-30	江苏豪森药业股份有限公司	Tipracil盐酸盐的新晶型及其制备方法
CN103980253B (zh)	2014-05-06	2015-07-08	济南百诺医药科技开发有限公司	一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法

2014
- 2014-06-17 DK DK14814354.8T patent/DK3012255T3/da active
- 2014-06-17 RU RU2017124790A patent/RU2674441C1/ru active
- 2014-06-17 SM SM20210689T patent/SMT202100689T1/it unknown
- 2014-06-17 KR KR1020167001279A patent/KR101806346B1/ko active Active
- 2014-06-17 SG SG10202007643SA patent/SG10202007643SA/en unknown
- 2014-06-17 RS RS20211505A patent/RS62691B1/sr unknown
- 2014-06-17 GE GEAP201814034A patent/GEAP201814034A/en unknown
- 2014-06-17 EP EP14814354.8A patent/EP3012255B1/en active Active
- 2014-06-17 PT PT148143548T patent/PT3012255T/pt unknown
- 2014-06-17 EP EP17204730.0A patent/EP3305779A1/en active Pending
- 2014-06-17 AU AU2014282281A patent/AU2014282281C1/en active Active
- 2014-06-17 WO PCT/JP2014/065985 patent/WO2014203877A1/ja not_active Ceased
- 2014-06-17 CA CA2985006A patent/CA2985006C/en active Active
- 2014-06-17 CN CN201610818347.6A patent/CN106967051A/zh active Pending
- 2014-06-17 SG SG10201710916YA patent/SG10201710916YA/en unknown
- 2014-06-17 SG SG10201912293UA patent/SG10201912293UA/en unknown
- 2014-06-17 SI SI201431915T patent/SI3012255T1/sl unknown
- 2014-06-17 CN CN201480000562.4A patent/CN104395307A/zh active Pending
- 2014-06-17 TW TW103120948A patent/TWI639592B/zh active
- 2014-06-17 GE GEAP201414034A patent/GEP20186875B/en unknown
- 2014-06-17 SG SG11201509189SA patent/SG11201509189SA/en unknown
- 2014-06-17 JP JP2015522923A patent/JP6364409B2/ja active Active
- 2014-06-17 ES ES14814354T patent/ES2898408T3/es active Active
- 2014-06-17 NZ NZ714090A patent/NZ714090A/en unknown
- 2014-06-17 GE GEAP201414225A patent/GEP20186841B/en unknown
- 2014-06-17 PL PL14814354T patent/PL3012255T3/pl unknown
- 2014-06-17 MX MX2015016986A patent/MX2015016986A/es active IP Right Grant
- 2014-06-17 MX MX2018009151A patent/MX383401B/es unknown
- 2014-06-17 RU RU2016100972A patent/RU2640417C2/ru active
- 2014-06-17 HU HUE14814354A patent/HUE057352T2/hu unknown
- 2014-06-17 UA UAA201600333A patent/UA112626C2/uk unknown
- 2014-06-17 MA MA38668A patent/MA38668B2/fr unknown
- 2014-06-17 LT LTEPPCT/JP2014/065985T patent/LT3012255T/lt unknown
- 2014-06-17 CN CN201910111208.3A patent/CN109912573A/zh active Pending
- 2014-06-17 CN CN201910933531.9A patent/CN110746403A/zh active Pending
- 2014-06-17 CA CA2914999A patent/CA2914999C/en active Active
- 2014-06-17 MY MYPI2018001900A patent/MY205261A/en unknown
- 2014-06-17 US US14/896,748 patent/US9527833B2/en active Active
- 2014-06-17 HK HK15103542.0A patent/HK1203071A1/xx unknown
- 2014-06-17 MY MYPI2015002887A patent/MY173410A/en unknown
- 2014-06-17 BR BR112015031619-0A patent/BR112015031619B1/pt active IP Right Grant
- 2014-06-17 HR HRP20211903TT patent/HRP20211903T1/hr unknown
2015
- 2015-12-17 PH PH12015502809A patent/PH12015502809B1/en unknown
2016
- 2016-11-16 US US15/352,858 patent/US10138223B2/en active Active
2017
- 2017-07-24 AU AU2017208215A patent/AU2017208215C1/en active Active
2018
- 2018-05-02 US US15/969,434 patent/US10457666B2/en active Active
- 2018-07-02 JP JP2018126102A patent/JP6526883B2/ja active Active
- 2018-08-20 AU AU2018219967A patent/AU2018219967C1/en active Active
2021
- 2021-12-07 CY CY20211101073T patent/CY1124868T1/el unknown

Also Published As

Publication number	Publication date
US10138223B2 (en)	2018-11-27
BR112015031619B1 (pt)	2023-01-17
BR112015031619A8 (pt)	2021-10-26
US10457666B2 (en)	2019-10-29
RU2016100972A (ru)	2017-07-21
EP3012255B1 (en)	2021-10-13
RS62691B1 (sr)	2022-01-31
SI3012255T1 (sl)	2022-01-31
WO2014203877A1 (ja)	2014-12-24
PT3012255T (pt)	2021-11-30
CA2914999C (en)	2018-03-20
ES2898408T3 (es)	2022-03-07
LT3012255T (lt)	2021-12-27
AU2018219967C1 (en)	2024-06-13
PL3012255T3 (pl)	2022-01-24
MY205261A (en)	2024-10-10
EP3305779A1 (en)	2018-04-11
CA2914999A1 (en)	2014-12-24
AU2014282281B2 (en)	2017-09-07
AU2014282281A1 (en)	2015-11-19
JP6526883B2 (ja)	2019-06-05
CN110746403A (zh)	2020-02-04
JPWO2014203877A1 (ja)	2017-02-23
JP6364409B2 (ja)	2018-07-25
CN106967051A (zh)	2017-07-21
US20180291005A1 (en)	2018-10-11
CN104395307A (zh)	2015-03-04
HK1203071A1 (en)	2015-10-16
CY1124868T1 (el)	2022-11-25
US9527833B2 (en)	2016-12-27
EP3012255A4 (en)	2017-02-08
KR101806346B1 (ko)	2017-12-07
US20170057949A1 (en)	2017-03-02
MX383401B (es)	2025-03-13
EP3012255A1 (en)	2016-04-27
US20160145241A1 (en)	2016-05-26
SG10201710916YA (en)	2018-02-27
AU2018219967A1 (en)	2018-09-13
SMT202100689T1 (it)	2022-01-10
TW201534601A (zh)	2015-09-16
RU2674441C1 (ru)	2018-12-10
CA2985006A1 (en)	2014-12-24
SG10201912293UA (en)	2020-02-27
NZ714090A (en)	2017-05-26
AU2018219967B2 (en)	2019-01-03
DK3012255T3 (da)	2021-12-06
CN109912573A (zh)	2019-06-21
HUE057352T2 (hu)	2022-05-28
CA2985006C (en)	2022-02-22
HRP20211903T1 (hr)	2022-03-04
GEAP201814034A (en)	2018-03-12
JP2018145204A (ja)	2018-09-20
MA38668B2 (fr)	2019-09-30
MY173410A (en)	2020-01-22
TWI639592B (zh)	2018-11-01
BR112015031619A2 (pt)	2017-07-25
AU2017208215C1 (en)	2024-07-11
UA112626C2 (uk)	2016-09-26
GEP20186875B (en)	2018-07-10
AU2014282281C1 (en)	2024-06-27
MA38668A1 (fr)	2018-05-31
SG11201509189SA (en)	2016-02-26
GEP20186841B (en)	2018-04-10
PH12015502809A1 (en)	2016-03-14
AU2017208215B2 (en)	2018-07-19
MX2015016986A (es)	2016-07-21
RU2640417C2 (ru)	2018-01-09
KR20160020560A (ko)	2016-02-23
AU2017208215A1 (en)	2017-08-10
PH12015502809B1 (en)	2016-03-14

Publication	Publication Date	Title
SG10201912293UA (en)	2020-02-27	Stable crystal form of tipiracil hydrochloride and crystallization method for the same
GB2518732B (en)	2015-11-18	Display device and method of manufacturing the same
ZA201507110B (en)	2017-09-27	Crystal modifications of elobixibat
IL260782B (en)	2019-02-28	Pyrrole derivative crystal and method for its production
IL240280A0 (en)	2015-09-24	Heterocyclic amides as kinase inhibitors
SG2014014054A (en)	2014-10-30	Device and Method for Alignment of substrates
IL239949B (en)	2020-09-30	Docking component and method for its production
SI2970123T1 (sl)	2019-12-31	Sol omekamtiv mekarbila in postopek za pripravo soli
SG11201507897SA (en)	2015-11-27	Salt of pyrazoloquinoline derivative, and crystal thereof
TWI561397B (en)	2016-12-11	Printbar and method of forming same
PL2945718T3 (pl)	2017-10-31	Układ oraz sposób krystalizacji
ZA201503159B (en)	2022-11-30	Small crystal ferrierite and method of making the same
IL245038B (en)	2019-11-28	Salt and crystal forms of plk–4 inhibitor
IL240356A0 (en)	2015-09-24	Laquinimod salt crystals and methods of preparation
EP3051176A4 (en)	2016-12-07	VIBRATION DAMPING MATERIAL AND METHOD FOR FIXING VIBRATION DAMPING MATERIAL
PT3309149T (pt)	2021-05-14	Cristal de 6-bromo-3-hidroxi-2-pirazinocarboxamida e processo para a sua produção
EP2959022A4 (en)	2017-01-11	Apparatus and method for crystallization
PL2778172T3 (pl)	2017-08-31	Stabilny krystaliczny monohydrat chlorowodorku epirubicyny i sposób wytwarzania
ZA201603637B (en)	2018-11-28	The crystalline forms of temozolomide and the method for preparing same
EP3030700A4 (en)	2016-09-07	METHOD AND APPARATUS FOR MANUFACTURING GROUP 13 ELEMENT NITRIDE CRYSTAL
GB201313778D0 (en)	2013-09-18	Liquid crystal device and method and manufacture
EP3030701A4 (en)	2016-09-21	DEVICE AND METHOD FOR PRODUCING A GROUP 13 NITRIDE CRYSTAL